BioSpace News Archive

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps who underwent endoscopic sinus surgery (ESS).

Sierra Oncology, Inc. today announced it has entered into a term loan agreement with Oxford Finance, LLC that is designed to primarily support the commercial preparation and potential launch of momelotinib, an investigational agent for the treatment of myelofibrosis, a rare form of blood cancer.

Loki Therapeutics today announced that it has secured seed financing led by Formic Ventures. With this additional funding, Loki has been able to raise a total of $2 million to date.

Checkpoint Therapeutics, Inc. today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting, to be held virtually during February.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences.

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the Edison Group ‘Open House’ Event, to be held virtually from 25-27 January 2022.

AtriCure, Inc. today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022.

Melzi Surgical announced today the appointment of Michael Layman to its Board of Directors.

Arcturus Therapeutics Holdings Inc. today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.